Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study
Joong-Won Park,Minshan Chen,Massimo Colombo,Lewis R. Roberts,Myron Schwartz,Pei-Jer Chen,Masatoshi Kudo,Philip J. Johnson,Samuel Wagner,L. Orsini,Morris Sherman +10 more
TLDR
The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC, from diagnosis to death.Abstract:
Background & Aims
Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal Article
Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases
Journal ArticleDOI
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
TL;DR: Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.
Journal ArticleDOI
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
TL;DR: Urgent measures that increase global awareness and tackle the metabolic risk factors are necessary to reduce the impending burden of NAFLD-related HCC and propose preventive strategies to tackle this growing problem.
Journal ArticleDOI
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
Pierce K. H. Chow,Mihir Gandhi,Say Beng Tan,Maung Win Khin,Ariunaa Khasbazar,Janus P. Ong,Su Pin Choo,Peng Chung Cheow,Chanisa Chotipanich,Kieron Lim,Laurentius A. Lesmana,Tjakra Manuaba,Boon Koon Yoong,Aloysius Raj,Chiong Soon Law,Ian Homer Y. Cua,Rolley Rey Lobo,Catherine Teh,Yun Hwan Kim,Yun Won Jong,Ho-Seong Han,Si Hyun Bae,Hyun-Ki Yoon,Rheun Chuan Lee,Chien Fu Hung,Cheng Yuan Peng,Po-Chin Liang,Adam Bartlett,Kenneth Y.Y. Kok,Choon Hua Thng,Albert S. C. Low,Anthony S. W. Goh,Kiang Hiong Tay,Richard Hoau Gong Lo,Brian K. P. Goh,David Chee Eng Ng,Ganesh Lekurwale,Wei Ming Liew,Val Gebski,Kenneth Seck Wai Mak,Khee Chee Soo +40 more
TL;DR: In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib, and the improved toxicity profile of RE may inform treatment choice in selected patients.
References
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken,Richard H. Creech,Douglass C. Tormey,John Horton,Thomas E. Davis,Eleanor T. McFadden,Paul P. Carbone +6 more
TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more